v3.26.1
Exclusive Option Agreement and Collaboration Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 03, 2025
Dec. 31, 2025
Oct. 31, 2025
Aug. 31, 2025
Mar. 31, 2026
Dec. 31, 2025
Exlcusive Option Agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Performance obligation revenue recognised         $ 4,600,000  
Amended Research Collaboration Agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Upfront, non-refundable fee       $ 6,500,000    
Expanded License Agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Upfront Payment           $ 6,000,000
Upfront, non-refundable fee     $ 6,000,000      
Deferred revenue recognized         0  
Deferred upfront payment         3,000,000  
Incyte Corporation            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Share price $ 3.98          
Share premium paid per share           $ 0.02
Total share premium paid           $ 100,000
Gross equity proceeds from issuance of common stock           24,900,000
Incyte Corporation | Asset Purchase Agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Option to acquire agreement amount $ 100,000,000          
Incyte Corporation | Asset Purchase Agreement | Maximum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Net sales on additional clinical and regulatory milestones, and single digit royalties 775,000,000          
Net potential cash payment 910,000,000          
Incyte Corporation | Exlcusive Option Agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Initial upfront payment received in cash $ 35,000,000          
Transaction price           35,100,000
Upfront payment and equity premium   $ 35,000,000       35,000,000
Research and development performance obligations   $ 35,100,000       $ 35,100,000
Upfront Payment         $ 28,000,000  
Incyte Corporation | Securities Purchase Agreement | Voting shares            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Shares sold   4,372,124        
Incyte Corporation | Securities Purchase Agreement | Non-voting Common Stock            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Shares sold 6,250,000          
Shares issued price per share $ 4          
Purchase of shares, value $ 25,000,000